Luxitaa Goenka1, Melvin George2, Sandhiya Selvarajan3. 1. Department of Clinical Pharmacology, SRM Medical College Hospital and Research Centre, SRM Nagar, Potheri, Kattankulathur, Chennai, 603203, Tamil Nadu, India. 2. Department of Clinical Pharmacology, SRM Medical College Hospital and Research Centre, SRM Nagar, Potheri, Kattankulathur, Chennai, 603203, Tamil Nadu, India. melvingeorge2003@gmail.com. 3. Department of Clinical Pharmacology, JIPMER, Puducherry, 605006, India.
Abstract
PURPOSE: Heart Failure (HF) continues to be associated with high mortality and morbidity. We attempted to identify the most common end points used in phase 3 clinical trials of heart failure and discuss their merits and demerits. METHODS: Literature evaluation was done using the databases PubMed and Clinicaltrials.gov from January 2010 to December 2016 to identify randomised clinical trials (RCTs) evaluating the effect of therapeutic drugs on heart failure. Following the literature search, the data on the primary end points were extracted from each of the selected trials. The most recurrent and important end points of Phase III clinical trials for HF over the last six years were identified for further discussion. RESULTS: From our search, it was observed that the most common end points used in trials with acute heart failure (AHF) were composite end point, dyspnea, CV death and most common end points used in trials with chronic heart failure (CHF) were composite end point, 6 minute walk test (6MWT), CV death or HFH, Vo2 max, all cause mortality, left ventricular ejection fraction (LVEF), and dyspnea. CONCLUSION: Choosing the appropriate end points is a critical step in the study design that could turn the tide in the beleaguered drug development pipeline of HF, resulting in the right molecule reaching the HF community.
PURPOSE:Heart Failure (HF) continues to be associated with high mortality and morbidity. We attempted to identify the most common end points used in phase 3 clinical trials of heart failure and discuss their merits and demerits. METHODS: Literature evaluation was done using the databases PubMed and Clinicaltrials.gov from January 2010 to December 2016 to identify randomised clinical trials (RCTs) evaluating the effect of therapeutic drugs on heart failure. Following the literature search, the data on the primary end points were extracted from each of the selected trials. The most recurrent and important end points of Phase III clinical trials for HF over the last six years were identified for further discussion. RESULTS: From our search, it was observed that the most common end points used in trials with acute heart failure (AHF) were composite end point, dyspnea, CV death and most common end points used in trials with chronic heart failure (CHF) were composite end point, 6 minute walk test (6MWT), CV death or HFH, Vo2 max, all cause mortality, left ventricular ejection fraction (LVEF), and dyspnea. CONCLUSION: Choosing the appropriate end points is a critical step in the study design that could turn the tide in the beleaguered drug development pipeline of HF, resulting in the right molecule reaching the HF community.
Entities:
Keywords:
Acute heart failure; Chronic heart failure; Composite end point; Dyspnea; Primary end points
Authors: José Luis Winter; Pablo F Castro; Juan Carlos Quintana; Rodrigo Altamirano; Andres Enriquez; Hugo E Verdejo; Jorge E Jalil; Rosemarie Mellado; Roberto Concepción; Pablo Sepúlveda; Victor Rossel; Luis Sepúlveda; Mario Chiong; Lorena García; Sergio Lavandero Journal: J Card Fail Date: 2014-01-09 Impact factor: 5.712
Authors: M T Slawsky; W S Colucci; S S Gottlieb; B H Greenberg; E Haeusslein; J Hare; S Hutchins; C V Leier; T H LeJemtel; E Loh; J Nicklas; D Ogilby; B N Singh; W Smith Journal: Circulation Date: 2000-10-31 Impact factor: 29.690
Authors: Mihai Gheorghiade; Kirkwood F Adams; John G F Cleland; Gad Cotter; G Michael Felker; Gerasimos S Filippatos; Gregg C Fonarow; Barry H Greenberg; Adrian F Hernandez; Sadiya Khan; Michel Komajda; Marvin A Konstam; Peter P Liu; Aldo P Maggioni; Barry M Massie; John J McMurray; Mandeep Mehra; Marco Metra; John O'Connell; Christopher M O'Connor; Peter S Pang; Ileana L Piña; Hani N Sabbah; John R Teerlink; James E Udelson; Clyde W Yancy; Faiez Zannad; Norman Stockbridge Journal: Am Heart J Date: 2009-06 Impact factor: 4.749
Authors: Faiez Zannad; Angeles Alonso Garcia; Stefan D Anker; Paul W Armstrong; Gonzalo Calvo; John G F Cleland; Jay N Cohn; Kenneth Dickstein; Michael J Domanski; Inger Ekman; Gerasimos S Filippatos; Mihai Gheorghiade; Adrian F Hernandez; Tiny Jaarsma; Joerg Koglin; Marvin Konstam; Stuart Kupfer; Aldo P Maggioni; Alexandre Mebazaa; Marco Metra; Christina Nowack; Burkert Pieske; Ileana L Piña; Stuart J Pocock; Piotr Ponikowski; Giuseppe Rosano; Luis M Ruilope; Frank Ruschitzka; Thomas Severin; Scott Solomon; Kenneth Stein; Norman L Stockbridge; Wendy Gattis Stough; Karl Swedberg; Luigi Tavazzi; Adriaan A Voors; Scott M Wasserman; Holger Woehrle; Andrew Zalewski; John J V McMurray Journal: Eur J Heart Fail Date: 2013-06-19 Impact factor: 15.534
Authors: John J V McMurray; Milton Packer; Akshay S Desai; Jim Gong; Martin P Lefkowitz; Adel R Rizkala; Jean Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile Journal: Eur J Heart Fail Date: 2013-04-05 Impact factor: 15.534
Authors: Victoria C Ziesenitz; Walter E Haefeli; Johannes N van den Anker; Matthias Gorenflo Journal: Eur J Clin Pharmacol Date: 2017-10-13 Impact factor: 2.953